Regal Beloit Corporation (NYSE:RBC) target has been increased by Baird after the company’s recent stock offering. The firm thinks that the offering could indicate potential futures M&A activity, but the firm also believes that there are potential earnings acceleration and stabilizing trends. Shares have an Outperform rating.
Ixia (NASDAQ:XXIA): After it met with Ixia’s management, Pacific Crest is convinced that the impact of the company’s opportunity to expand into network production has not been fully appreciated by investors. The firm believes that Ixia would be able to significantly extend its business with mobile carriers, and it keepsits Outperform rating on the stock.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ): According to UBS, the FDA denial of Jazz’s 2nd Citizen’s Petition did not come as a surprise, and the firm expects a minimal pullback in shares. The firm still sees regulatory hurdles for generic competition for Xyrem, and it keeps its Buy rating and $64 price target on the stock.
Global Payments Inc. (NYSE:GPN): Wells Fargo predicts that fears regarding Global Payments’ competitors should settle down, since the company will probably announce partnerships that should be seen as positive by investors. The firm sees the stock as having “an above-average chance of being a strong performer in 2013,” and it keeps its Outperform rating on the stock.
Don’t Miss: Why is This Analyst Worried About Apple?